Roche's Q1 2026 earnings conference call, held April 23, 2026, centered on three converging pipeline signals: an imminent fenebrutinib NDA filing carrying an unresolved fatal AE imbalance, a giredestrant regulatory timeline anchored to the adjuvant breast cancer setting after a first-line Phase III failure, and a materially accelerated obesity franchise now entering Phase III with enicepatide while planning a mid-2026 combination study with petrelintide.
Key Strategic Signals
[Fenebrutinib / MS]: Following positive results from the FENhance 1 Phase III trial in relapsing MS — the last of three positive Phase III studies across RMS and PPMS — Roche confirmed a regulatory filing in "the coming months," executives said. Management reiterated peak sales potential above CHF 3 billion, suggesting fenebrutinib represents the first BTK inhibitor with positive Phase III data across both RMS and PPMS.
[Giredestrant / Breast Cancer]: Roche filed giredestrant in the adjuvant ER-positive, HER2-negative setting (lidERA) using a priority review voucher, with approval expected before year-end, executives said. A PDUFA date of December 18 was set for the second-line-plus evERA indication, while management reframed the commercial opportunity around adjuvant — estimated at roughly 70% of a USD 20–30 billion total SERD market — following the Phase III persevERA failure in first-line metastatic breast cancer.
[Enicepatide + Petrelintide / Obesity]: Roche initiated two Phase III obesity trials for enicepatide (formerly CT-388, a GLP-1/GIP dual agonist) in Q1 2026 and announced a Phase II combination study with petrelintide (amylin analog, partnered with Zealand) set to enroll its first patient around mid-2026, executives said. Emugrobart (RO7204239) was discontinued in SMA and FSHD following negative Phase II data, however development continues for obesity, specifically as a muscle-sparing agent in combination with weight-loss drugs.
Analyst Pressure Points
[Fenebrutinib Safety / Approvability]: Analysts pressed management on a fatal AE imbalance observed across all three fenebrutinib Phase III MS trials — including suicidality cases — and whether the FDA had signaled concern about approvability. Teresa Graham, CEO of Roche Pharmaceuticals, said discussions with the FDA had been "very productive" and that the company was "confident in the favorable risk-benefit profile," while acknowledging that suicidality in the MS population would "likely require more data and more time" to fully characterize.